New York, Jan 20, 2026, 11:54 EST — Regular session
- Shares of UnitedHealth Group Incorporated climbed roughly 1.3% in late morning trading, bucking the broader market downturn.
- Evercore ISI kicked off coverage with a $400 price target, and Bernstein raised its target to $444, according to TipRanks.
- Options pricing signals heightened volatility ahead of next week’s earnings and 2026 guidance.
Shares of UnitedHealth Group Incorporated (NYSE: UNH) climbed 1.3% to $335.30 Tuesday, standing out amid a wider Wall Street selloff. The gains came as traders processed fresh tariff threats from President Donald Trump. One strategist cautioned that the headlines would “drive angst and concern about what the future holds.” Reuters
UnitedHealth plans to release its full-year 2025 earnings and 2026 forecast on Jan. 27, ahead of the market open, followed by a teleconference at 8:00 a.m. ET.
UnitedHealth’s results carry weight as a barometer for managed-care, especially with investors on edge over medical-cost trends ahead of the first major insurer earnings. Medicare Advantage — government-funded, privately managed senior plans — is a key area where minor changes in claims can cause major profit swings.
Analysts are growing more vocal about a turnaround. Elizabeth Anderson at Evercore ISI kicked off coverage with a $400 price target, dubbing 2026 a “transition year.” Meanwhile, Bernstein’s Lance Wilkes nudged his target up to $444 from $440, maintaining a buy rating, TipRanks reported. TipRanks
Options traders appeared divided but leaned bullish, with calls outnumbering puts and a put/call ratio at 0.39—well below the usual 1.18, according to TipRanks’ TheFly. Implied volatility, which measures expected price swings, pointed to a daily move around $8.24.
Other managed-care stocks moved unevenly. Humana jumped roughly 2%, CVS Health climbed around 2%, Cigna inched up, and Elevance slipped a bit. The Health Care Select Sector SPDR Fund fell about 0.2%.
The policy environment isn’t providing much support. The White House unveiled a plan aimed at cutting drug prices and insurance premiums while holding insurers accountable, yet it gave no clear timeline. Analysts remain skeptical about significant healthcare reforms passing swiftly in a split Congress, Reuters reported.
Traders are zeroing in on UnitedHealth to see if pricing aligns with claims costs, while also scrutinizing management’s comments on membership and insurance margins. Optum’s results will draw attention once more, following a stretch of mixed performances.
The risk issue hasn’t disappeared. A U.S. Senate committee report released this month accused UnitedHealth of employing “aggressive” risk-adjustment coding to boost Medicare Advantage payments. UnitedHealth pushed back, stating its programs meet all requirements and have shown “demonstrated sustained adherence” during government audits. Reuters
Jan. 27 marks the next major catalyst. Investors want a clear 2026 outlook and more precise guidance on what will change—and what will stay the same—as Washington continues to scrutinize the economics of U.S. health insurance.
